Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.34 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19984396 | 0.80 | HTR1A (0.34) | HTR1ARAPGEF3ADRA1A | |
| SCHEMBL19984390 | 0.77 | HTR1A (0.32) | HTR1ARAPGEF3ADRA1A | |
| SCHEMBL19984130 | 0.74 | HTR1A (0.37) | HTR1AADRA1A | |
| SCHEMBL5777202 | 0.74 | HTR1A (0.50) | HTR1AADRA1A | |
| SCHEMBL19971712 | 0.72 | HTR1A (0.41) | HTR1AADRA1A | |
| SCHEMBL19984059 | 0.70 | HTR1A (0.54) | HTR1A | |
| SCHEMBL19984126 | 0.69 | HTR1A (0.55) | HTR1A | |
| SCHEMBL19984381 | 0.68 | HTR1A (0.39) | HTR1AADRA1A | |
| SCHEMBL5799486 | 0.68 | HSD11B1 (0.51) | HTR1A | |
| SCHEMBL19984209 | 0.66 | HTR1A (0.45) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885RAPGEF3 2319/4885ADRA1A 82/4885 |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885RAPGEF3 2319/4885ADRA1A 82/4885 |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885RAPGEF3 2319/4885ADRA1A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.